Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789191 · ClinicalTrials.gov registry record · Phase 3
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
NCT00789191 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 222 participants.
The verdict
NCT00789191, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.
Interventions
- DRUG metformin
- DRUG insulin detemir
- DRUG sitagliptin
- DRUG sulphonylurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789191
The ClinicalTrials.gov registry entry for NCT00789191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.
NCT00789191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789191 about?
NCT00789191 is a clinical study titled "Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes". This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.
What is the current status of trial NCT00789191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2008-11. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00789191?
The interventions under investigation include: metformin (DRUG), insulin detemir (DRUG), sitagliptin (DRUG), sulphonylurea (DRUG).
Who is sponsoring clinical trial NCT00789191?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.